Testing metformin in older adults with chronic obstructive pulmonary disease
Tests metformin's safety and effect on aging markers in adults with COPD.
Plain-language title generated from the registry record
Registry title: Investigating Senolytic Properties in Pulmonary Rehabilitation and Metformin in COPD Exacerbations
Key facts
- Where
- Durham, United StatesSee the site
- Phase
- Phase 1
Where in United States
- Duke Asthma Allergy and Airway CenterDurham, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Duke University
- Trial code
- NCT07275359
- Record updated
- 3 November 2026
- Original description
The purpose of this study is to investigate the safety and tolerability of Metformin and how it changes blood markers associated with aging in persons who have chronic obstructive pulmonary disease (COPD) who do not have diabetes.Read full original descriptionShow less
Investigating Senolytic Properties in Pulmonary Rehabilitation and Metformin in COPD Exacerbations
The purpose of this study is to investigate the safety and tolerability of Metformin and how it changes blood markers associated with aging in persons who have chronic obstructive pulmonary disease (COPD) who do not have diabetes.
Inclusion: Age 65 and older; History of COPD defined by spirometry demonstrating FEV1/FVC < 70%; 10 or more tobacco pack year history; History of frequent exacerbations defined as: 1 severe (i.e., COPD hospitalization) or 2 moderate (i.e., outpatient treated exacerbations) in the previous 12 months.
Exclusion: Diabetes or actively being treated with metformin; Persons with an unstable medical condition (including but not limited to unstable angina, acute heart failure exacerbation, acute neurological symptoms) or COPD exacerbation within 30 days prior to enrollment will be excluded; Active treatment with Carbonic Anhydrase Inhibitors including but not limited to topiramate, zonisamide, acetazolamide, diclofenamide; Metformin allergy; History of lactic acidosis not explained by acute, severe illness; History of low vitamin B12 levels and unwilling to begin standard of care treatment for low vitamin B12 levels; Cognitive impairment; Dementia; Alcohol use disorder; Hepatic impairment defined as history of cirrhosis or abnormal liver function tests (e.g., alanine transaminase (ALT): 7-55 units per liter (U/L), aspartate transaminase (AST): 8-48 U/L, alkaline phosphatase (ALP): 40-129 U/L, or bilirubin: 0.1-1.2 milligrams per deciliter (mg/dL)); Renal impairment defined as eGFR < 60 mL/min/1.73m2; Heart failure with reduced ejection fraction < 50%; Disability preventing in-person visits.